Clyde's In Silico Services:
Modelling the Future
Clyde Biosciences has developed a computational model of electrophysiological and intracellular calcium signals in human iPS-derived cardiac cells.
Our model integrates 20 ion channels, and 4 ion pumps and exchangers, to provide a detailed quantitative description of drug effects on membrane potential and intracellular calcium signals.
This model is used as a tool to provide detail on the effects of drugs on human cardiac electrophysiology and arrhythmogenesis.
Use of in silico techniques is a cornerstone of CiPA – offering a potential index of proarrhythmic risk.
Clyde works with leading providers of iPS-CMs to develop accurate, predictive models of their cell lines. Once validated, those models can then be applied to drug candidates from biopharma companies to provide accurate in silico measurements of their ion channel actions.
Major benefits include:
A complete picture of your compounds’ predicted effects on cardiac ion channels
Rapid turnaround providing meaningful data within your timescales
Placing you at the leading edge of predictive cardiac toxicology
In Silico modeling of hiPSC cardiomyocyte electrophysiology
In Silico modelling of iPSC cardiomyocytes using the Paci model (Paci et al 2013). This allows prediction of the relative inhibition of ion channels. Shown here are examples of 50% inhibition of ICaL and IKr.
Start a study with Clyde
To enquire about how Clyde could help with your project complete the enquiry form below and we’ll be get back to you as soon as we can. Alternatively email us at info@clydebio.com